Clinical trial data support the NDA for TEV-'749, demonstrating that once-monthly olanzapine improves symptoms in patients with schizophrenia. The Food and Drug Administration (FDA) has accepted for ...

PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE ...

Zyprexa Intramuscular Warnings/Precautions Warnings/Precautions Relprevv: post-injection delirum/sedation syndrome: monitor after each injection. Elderly with dementia-related psychosis (not approved ...

(RTTNews) - Medincell SA (MEDCL.PA) reported that new long-term safety data from the completed Phase 3 SOLARIS trial support the potential of Olanzapine LAI (TEV-749) as the first long-acting ...

Federal regulators are investigating the deaths of two patients who received injections of a longer-lasting version of Eli Lilly’s antipsychotic Zyprexa. The Food and Drug Administration said Tuesday ...

MONTPELLIER, France--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced during the 22 nd Annual Global Healthcare ...

PARSIPPANY, N.J. and TEL AVIV - Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Medincell (Euronext:MEDCL) announced today that the U.S. Food and Drug Administration has accepted their ...

Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-'749) and its long-term systemic ...

To fuel CEO Richard Francis’s “pivot to growth” plan, Teva has turned to royalty financing to fuel the accelerated development of a pipeline antipsychotic drug in its innovation portfolio. Teva has ...

March 23 (Reuters) - The U.S. Food and Drug Administration said it would not recommend changes to the prescribing or use of Eli Lilly and Co's schizophrenia drug after a review of two deaths. Elevated ...